181 related articles for article (PubMed ID: 24258993)
21. Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS).
Saponara M; Urbini M; Astolfi A; Indio V; Ercolani G; Del Gaudio M; Santini D; Pirini MG; Fiorentino M; Nannini M; Lolli C; Mandrioli A; Gatto L; Brandi G; Biasco G; Pinna AD; Pantaleo MA
Oncotarget; 2015 Dec; 6(39):42243-57. PubMed ID: 26544626
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
[TBL] [Abstract][Full Text] [Related]
23. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
Neumann J; Wehweck L; Maatz S; Engel J; Kirchner T; Jung A
Virchows Arch; 2013 Oct; 463(4):509-23. PubMed ID: 23934607
[TBL] [Abstract][Full Text] [Related]
24. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.
Kong Y; Si L; Li Y; Wu X; Xu X; Dai J; Tang H; Ma M; Chi Z; Sheng X; Cui C; Guo J
Clin Cancer Res; 2016 Feb; 22(4):1018-27. PubMed ID: 26490311
[TBL] [Abstract][Full Text] [Related]
25. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
26. Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation.
Haryuni RD; Watabe S; Yamaguchi A; Fukushi Y; Tanaka T; Kawasaki Y; Zhou Y; Yokoyama S; Sakurai H
Biochem Biophys Res Commun; 2019 Jun; 514(2):456-461. PubMed ID: 31053301
[TBL] [Abstract][Full Text] [Related]
27. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
[TBL] [Abstract][Full Text] [Related]
28. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
[TBL] [Abstract][Full Text] [Related]
29. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations.
Platz A; Ringborg U; Brahme EM; Lagerlöf B
Melanoma Res; 1994 Jun; 4(3):169-77. PubMed ID: 7919962
[TBL] [Abstract][Full Text] [Related]
30. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
31. Oncogenes in melanoma: an update.
Kunz M
Eur J Cell Biol; 2014; 93(1-2):1-10. PubMed ID: 24468268
[TBL] [Abstract][Full Text] [Related]
32. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
33. Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.
Jeck WR; Parker J; Carson CC; Shields JM; Sambade MJ; Peters EC; Burd CE; Thomas NE; Chiang DY; Liu W; Eberhard DA; Ollila D; Grilley-Olson J; Moschos S; Neil Hayes D; Sharpless NE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):653-63. PubMed ID: 24628946
[TBL] [Abstract][Full Text] [Related]
34. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Torres S; González Á; Cunquero Tomas AJ; Calabuig Fariñas S; Ferrero M; Mirda D; Sirera R; Jantus-Lewintre E; Camps C
Expert Rev Mol Diagn; 2020 Jun; 20(6):575-582. PubMed ID: 32011193
[TBL] [Abstract][Full Text] [Related]
35. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
Marks JL; McLellan MD; Zakowski MF; Lash AE; Kasai Y; Broderick S; Sarkaria IS; Pham D; Singh B; Miner TL; Fewell GA; Fulton LL; Mardis ER; Wilson RK; Kris MG; Rusch VW; Varmus H; Pao W
PLoS One; 2007 May; 2(5):e426. PubMed ID: 17487277
[TBL] [Abstract][Full Text] [Related]
36. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy.
Law AJ; Wang Y; Sei Y; O'Donnell P; Piantadosi P; Papaleo F; Straub RE; Huang W; Thomas CJ; Vakkalanka R; Besterman AD; Lipska BK; Hyde TM; Harrison PJ; Kleinman JE; Weinberger DR
Proc Natl Acad Sci U S A; 2012 Jul; 109(30):12165-70. PubMed ID: 22689948
[TBL] [Abstract][Full Text] [Related]
37. Mutation analysis of the CDKN2A promoter in Australian melanoma families.
Pollock PM; Stark MS; Palmer JM; Walters MK; Aitken JF; Martin NG; Hayward NK
Genes Chromosomes Cancer; 2001 Sep; 32(1):89-94. PubMed ID: 11477665
[TBL] [Abstract][Full Text] [Related]
38. BRAF mutation detection and identification by cycling temperature capillary electrophoresis.
Hinselwood DC; Abrahamsen TW; Ekstrøm PO
Electrophoresis; 2005 Jun; 26(13):2553-61. PubMed ID: 15948220
[TBL] [Abstract][Full Text] [Related]
39. Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype.
Telesco SE; Vadigepalli R; Radhakrishnan R
Biotechnol J; 2013 Dec; 8(12):1452-64. PubMed ID: 24318637
[TBL] [Abstract][Full Text] [Related]
40. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
